Home/Pipeline/TLR-004

TLR-004

Inflammatory Bowel Disease

PreclinicalActive

Key Facts

Indication

Inflammatory Bowel Disease

Phase

Preclinical

Status

Active

Company

Tilray

About Tilray

Tilray's mission is to be the world's leading cannabis-focused consumer branded goods and pharmaceutical company. Its key achievements include establishing one of the largest global footprints in cannabis cultivation and distribution, successfully merging with Aphria to create an industry leader, and building a clinical pipeline targeting serious conditions like glioblastoma and epilepsy. The company's strategy is to drive growth through its diversified portfolio—spanning cannabis, beverage alcohol, and wellness products—while investing in high-value pharmaceutical R&D to unlock long-term value from cannabinoid science.

View full company profile

Therapeutic Areas

Oncology Neurology Inflammatory Conditions

Other Inflammatory Bowel Disease Drugs

Drug	Company	Phase	Status
DVI-001	Divamics	Preclinical	Approaching PCC selection
DVI-002	Divamics	Preclinical	Lead optimization
Turq-101	Turquoise Biotechnologies	Preclinical	Active
GS-4875	Gilead	Phase 2	Active
Function-based Consortium for IBD	PharmaBiome	Pre-clinical	Active
Galapagos Collaboration	Scipher Medicine	Discovery/Pre-clinical	Active
IBD Subclassification	Bio-Me	Research	Active
Anti-iRhom2 antibodies	SciRhom	Pre-clinical	Active
IBD Multi-omics Dataset	Ovation.io	Commercial	Active
Noa‑001	Noa Therapeutics	Preclinical	Active
Inflectra	EMS	Phase 3	Active
IW-601	ImmuneWalk Therapeutics	Preclinical	Active